» Articles » PMID: 28993411

Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors

Abstract

Hepatic steatosis is a strong risk factor for the development of hepatocellular carcinoma (HCC), yet little is known about the molecular pathology associated with this factor. In this study, we performed a forward genetic screen using (SB) transposon insertional mutagenesis in mice treated to induce hepatic steatosis and compared the results to human HCC data. In humans, we determined that steatosis increased the proportion of female HCC patients, a pattern also reflected in mice. Our genetic screen identified 203 candidate steatosis-associated HCC genes, many of which are altered in human HCC and are members of established HCC-driving signaling pathways. The protein kinase A/cyclic AMP signaling pathway was altered frequently in mouse and human steatosis-associated HCC. We found that activated PKA expression drove steatosis-specific liver tumorigenesis in a mouse model. Another candidate HCC driver, the -acetyltransferase , which we found to be overexpressed in human steatosis-associated HCC and associated with decreased survival in human HCC, also drove liver tumorigenesis in a steatotic mouse model. This study identifies genes and pathways promoting HCC that may represent novel targets for prevention and treatment in the context of hepatic steatosis, an area of rapidly growing clinical significance. .

Citing Articles

Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis.

Xie H, Zhang K, Yin H, Zhang S, Pan S, Wu R J Immunother Cancer. 2025; 13(2).

PMID: 39939141 PMC: 11822433. DOI: 10.1136/jitc-2024-010301.


Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model.

Chiu V, Yee C, Main N, Stevanovski I, Watt M, Wilson T Clin Sci (Lond). 2024; 138(19):1227-1248.

PMID: 39254423 PMC: 11427747. DOI: 10.1042/CS20240560.


N-Acetyltransferase 10 represses Uqcr11 and Uqcrb independently of ac4C modification to promote heart regeneration.

Ma W, Tian Y, Shi L, Liang J, Ouyang Q, Li J Nat Commun. 2024; 15(1):2137.

PMID: 38459019 PMC: 10923914. DOI: 10.1038/s41467-024-46458-7.


Dissecting the oncogenic properties of essential RNA-modifying enzymes: a focus on NAT10.

Dalhat M, Narayan S, Serio H, Arango D Oncogene. 2024; 43(15):1077-1086.

PMID: 38409550 PMC: 11092965. DOI: 10.1038/s41388-024-02975-9.


Advances in transposable elements: from mechanisms to applications in mammalian genomics.

Han M, Perkins M, Novaes L, Xu T, Chang H Front Genet. 2023; 14:1290146.

PMID: 38098473 PMC: 10719622. DOI: 10.3389/fgene.2023.1290146.


References
1.
Cole S, Sood A . Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2011; 18(5):1201-6. PMC: 3294063. DOI: 10.1158/1078-0432.CCR-11-0641. View

2.
Bray N, Pimentel H, Melsted P, Pachter L . Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016; 34(5):525-7. DOI: 10.1038/nbt.3519. View

3.
Seitz H, Stickel F . Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006; 387(4):349-60. DOI: 10.1515/BC.2006.047. View

4.
Tan T, Miow Q, Huang R, Wong M, Ye J, Lau J . Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med. 2013; 5(7):1051-66. PMC: 3721473. DOI: 10.1002/emmm.201201823. View

5.
Collier L, Carlson C, Ravimohan S, Dupuy A, Largaespada D . Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005; 436(7048):272-6. DOI: 10.1038/nature03681. View